SCHEMBL1775244

SCHEMBL1775244

NS(=O)(=O)c1cncc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.59
CA1 P00915 7/20 0.46
CA2 P00918 7/20 0.46
CA9 Q16790 6/20 0.46
CA12 O43570 3/20 0.46
CA4 P22748 3/20 0.46
CA6 P23280 3/20 0.46
CA5A P35218 3/20 0.46
CA7 P43166 3/20 0.46
CA14 Q9ULX7 3/20 0.46
CA5B Q9Y2D0 3/20 0.46
CA13 Q8N1Q1 2/20 0.46
CA3 P07451 1/20 0.46
HCAR2 Q8TDS4 1/20 0.41
CDK2 P24941 1/20 0.40
PTGES2 Q9H7Z7 1/20 0.40
LMNA P02545 1/20 0.39
CYP2C9 P11712 1/20 0.39
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11690551 0.84 APLNR (0.71) APLNRCA1CA2CA9CA12
SCHEMBL1828079 0.80 HCAR2 (0.42) APLNRHCAR2TDP1S100A9PTGS1
SCHEMBL12417957 0.78 PTGS2 (0.48) HCAR2S100A9PIK3CDPIK3CGPTGS1
SCHEMBL31097440 0.78 PTGS2 (0.48) HCAR2S100A9PIK3CDPIK3CGPTGS1
SCHEMBL31344514 0.78 HCAR2 (0.45) APLNRHCAR2S100A9PTGS1PTGS2
Hydrochloric Acid SCHEMBL28159283 0.77 HCAR2 (0.44) APLNRHCAR2S100A9PTGS1PTGS2
SCHEMBL3662570 0.76 APLNR (0.61) APLNRCA1CA2CA9CA12
SCHEMBL28053345 0.75 APLNR (0.50) APLNRCA1CA2CA9CA12
SCHEMBL7968311 0.75 HCAR2 (0.38) APLNRHCAR2S100A9PTGS1PTGS2
SCHEMBL7974914 0.75 HCAR2 (0.38) APLNRHCAR2LMNAL3MBTL1S100A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 WO claimed
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 WO disclosed
US-7943629-B2 Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example BAYER SCHERING PHARMA AG (DE) 2011-05-17 US disclosed
EP-2029552-B1 SULFIMIDES AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2010-09-22 EP disclosed
EP-2029552-A1 SULFIMIDES AS PROTEIN KINASE INHIBITORS Bayer Schering Pharma AG (DE) 2009-03-04 EP disclosed
US-20080058358-A1 SULPHIMIDES AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed
WO-2007140957-A1 SULFIMIDES AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058358-A1 SULPHIMIDES AS PROTEIN KINASE INHIBITORS PRKCE, BRAF, PACSIN2 APLNR 4237/4885CA1 2211/4885CA2 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.